“In a pivotal 39-week dermal repeat dose toxicity study in minipigs, clascoterone cream (concentrations: 0% [untreated], 0% [vehicle], 1%, 2.5%, and 5% applied to ~10% body surface area (BSA);”
✓ VerifiedFDA multi-discipline review, p. 35Source ↗
Pivotal GLP studies
26-week subcutaneous rat and 39-week dermal minipig studies
“Subcutaneous repeat dose toxicity studies in rats (up to 26 weeks in duration); dermal repeat dose toxicity studies in minipigs (up to 39 weeks in duration)”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Route in tox
Subcutaneous (rat) and dermal (minipig)
“Subcutaneous repeat dose toxicity studies in rats (up to 26 weeks in duration); dermal repeat dose toxicity studies in minipigs (up to 39 weeks in duration)”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗